These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30566486)

  • 1. Response to anti-tuberculosis treatment by people over age 60 in Kampala, Uganda.
    Kirirabwa NS; Kimuli D; DeJene S; Nanziri C; Birabwa E; Okello DA; Suarez PG; Kasozi S; Byaruhanga R; Lukoye D
    PLoS One; 2018; 13(12):e0208390. PubMed ID: 30566486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.
    Jones-López EC; Ayakaka I; Levin J; Reilly N; Mumbowa F; Dryden-Peterson S; Nyakoojo G; Fennelly K; Temple B; Nakubulwa S; Joloba ML; Okwera A; Eisenach KD; McNerney R; Elliott AM; Ellner JJ; Smith PG; Mugerwa RD
    PLoS Med; 2011 Mar; 8(3):e1000427. PubMed ID: 21423586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis retreatment 'others' in comparison with classical retreatment cases; a retrospective cohort review.
    Nabukenya-Mudiope MG; Kawuma HJ; Brouwer M; Mudiope P; Vassall A
    BMC Public Health; 2015 Sep; 15():840. PubMed ID: 26330223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis risk factors among tuberculosis patients in Kampala, Uganda: implications for tuberculosis control.
    Kirenga BJ; Ssengooba W; Muwonge C; Nakiyingi L; Kyaligonza S; Kasozi S; Mugabe F; Boeree M; Joloba M; Okwera A
    BMC Public Health; 2015 Jan; 15():13. PubMed ID: 25604986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National Referral Hospital, Kampala, Uganda.
    Batte C; Namusobya MS; Kirabo R; Mukisa J; Adakun S; Katamba A
    Afr Health Sci; 2021 Mar; 21(1):238-247. PubMed ID: 34394303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study.
    Kizito E; Musaazi J; Mutesasira K; Twinomugisha F; Namwanje H; Kiyemba T; Freitas Lopez DB; Nicholas NS; Nkolo A; Birabwa E; Dejene S; Zawedde-Muyanja S
    BMC Infect Dis; 2021 Mar; 21(1):292. PubMed ID: 33752637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the drug-resistant tuberculosis challenge through implementing a mixed model of care in Uganda.
    Kasozi S; Kirirabwa NS; Kimuli D; Luwaga H; Kizito E; Turyahabwe S; Lukoye D; Byaruhanga R; Chen L; Suarez P
    PLoS One; 2020; 15(12):e0244451. PubMed ID: 33373997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile and response to anti-tuberculosis treatment among elderly tuberculosis patients treated under the TB Control programme in South India.
    Velayutham BR; Nair D; Chandrasekaran V; Raman B; Sekar G; Watson B; Charles N; Malaisamy M; Thomas A; Swaminathan S
    PLoS One; 2014; 9(3):e88045. PubMed ID: 24618888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home-Based and Facility-Based Directly Observed Therapy of Tuberculosis Treatment under Programmatic Conditions in Urban Tanzania.
    Mhimbira F; Hella J; Maroa T; Kisandu S; Chiryamkubi M; Said K; Mhalu G; Mkopi A; Mutayoba B; Reither K; Gagneux S; Fenner L
    PLoS One; 2016; 11(8):e0161171. PubMed ID: 27513331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and treatment outcomes among patients with tuberculosis in Bangkok and Nonthaburi, Thailand.
    Manosuthi W; Kawkitinarong K; Suwanpimolkul G; Chokbumrungsuk C; Jirawattanapisal T; Ruxrungtham K; Akksilp S
    Southeast Asian J Trop Med Public Health; 2012 Nov; 43(6):1426-36. PubMed ID: 23413706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.
    Hafkin J; Modongo C; Newcomb C; Lowenthal E; MacGregor RR; Steenhoff AP; Friedman H; Bisson GP
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):348-53. PubMed ID: 23321297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
    Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.
    Ezati N; Lukoye D; Wampande EM; Musisi K; Kasule GW; Cobelens FG; Kateete DP; Joloba ML
    BMC Infect Dis; 2014 Dec; 14():703. PubMed ID: 25523472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.
    Sagwa E; Ruswa N; Musasa JP; Mantel-Teeuwisse AK
    Drug Saf; 2013 Nov; 36(11):1087-96. PubMed ID: 23917883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
    Woldeyohannes D; Assefa T; Aman R; Tekalegn Y; Hailemariam Z
    PLoS One; 2019; 14(10):e0224025. PubMed ID: 31665154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes of drug-resistant tuberculosis in people living with HIV in Odesa province, Ukraine, 2014-2016.
    Yesypenko S; Grigoryan R; Sereda Y; Denisuk O; Kovtunovich L; Rybak T; Postnov O; Neduzhko O; Antonyak S; Bespoyasnaya V
    J Infect Dev Ctries; 2020 Nov; 14(11.1):88S-93S. PubMed ID: 33226965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda.
    Cattamanchi A; Crowder R; Kityamuwesi A; Kiwanuka N; Lamunu M; Namale C; Tinka LK; Nakate AS; Ggita J; Turimumahoro P; Babirye D; Oyuku D; Berger C; Tucker A; Patel D; Sammann A; Turyahabwe S; Dowdy D; Katamba A
    PLoS Med; 2021 May; 18(5):e1003628. PubMed ID: 33956802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.